Wegovy Without Insurance: How to Cut the Cost

Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through partner links, at no extra cost to you. Editorial independence preserved — recommendations based on provider compliance and patient outcomes, not commission rates. This article is informational and is not medical advice.

Wegovy’s list price is about $1,350 a month. For years, that number defined the decision: either your insurance covered Wegovy, or you faced a cost most households simply could not absorb. In 2026, that binary has broken open. A new Medicare program, manufacturer self-pay pricing, an oral version of the drug and a federal pricing portal have all changed what people actually pay — often dramatically. The list price now tells you very little. What matters is which payment route fits your situation. This guide maps them: commercial insurance, Medicare, cash, and the compounded alternative.

The List Price — and Why 2026 Changed the Conversation

Wegovy lists at roughly $1,350 a month, and that figure applies to both the once-weekly injection and the daily oral tablet. Pharmacy discount cards trim it only modestly — cash prices with a discount card stay well above the manufacturer’s own self-pay pricing — so the list price is best treated as a starting point you will almost certainly never actually pay.

What changed in 2026 is the number of routes around it. Wegovy is FDA-approved for chronic weight management and, separately, to reduce the risk of major cardiovascular events in adults with heart disease who also have obesity or overweight. That second, cardiovascular use matters for coverage. Layered on top are a manufacturer self-pay program, a new oral form, a federal pricing portal and — most significantly for older Americans — a new Medicare pathway. Your real cost depends entirely on which of these applies to you.

If You Have Commercial Insurance

For people with commercial or employer insurance, the first question is whether the plan covers weight-loss medication at all — and many still do not. Coverage of GLP-1 drugs for weight management remains inconsistent: some plans cover Wegovy with prior authorization and BMI requirements, while others exclude weight-loss drugs as a category.

If your plan does cover Wegovy, the Wegovy Savings Card can bring your out-of-pocket cost down to as little as $25 a month. The card is only for patients with eligible commercial insurance; it cannot be used with Medicare, Medicaid or Tricare.

If your plan does not cover Wegovy — or covers it only after a prior-authorization fight — you are effectively in the same position as an uninsured patient, and the cash routes below become the relevant ones. It is worth checking your formulary before assuming either way: coverage for the cardiovascular indication, in particular, is sometimes available even on plans that exclude weight-loss drugs. Medicaid is a separate question again — coverage of weight-loss medication under Medicaid varies considerably from state to state, so Medicaid beneficiaries should check directly with their state program.

If You Have Medicare — the New GLP-1 Bridge

Medicare has historically been a closed door for Wegovy used for weight loss. By law, Medicare cannot cover drugs prescribed solely for weight reduction, which left beneficiaries paying the full price out of pocket. Two things change that picture in 2026.

First, standard Medicare Part D can already cover Wegovy for its cardiovascular indication — to reduce the risk of heart attack and stroke in beneficiaries with established heart disease and obesity or overweight. If you qualify on those grounds, Wegovy may be covered through your normal Part D benefit, subject to your plan’s rules.

Second, and bigger: the Medicare GLP-1 Bridge. Beginning July 1, 2026, this CMS program gives eligible Part D beneficiaries access to GLP-1 medications approved for weight loss — including Wegovy, in both injection and tablet form — for a flat $50 monthly copay. The Bridge is a temporary demonstration program running through December 31, 2027, designed to precede a longer-term Medicare model. To qualify you must be enrolled in a Part D plan and meet the clinical criteria: a BMI of 35 or higher, or 27 or higher together with a related health condition, plus prior authorization.

One detail worth knowing: the Bridge operates outside the standard Part D benefit, so the $50 copay does not count toward your deductible or your annual out-of-pocket cap, and other coupons cannot be stacked on top of it. For a Medicare beneficiary who has been priced out of Wegovy entirely, a $50 monthly copay is a substantial change — but note the end date. The Bridge is, by design, a bridge.

Paying Cash — Self-Pay, the Pill, and Compounded

If you are uninsured, or insured without weight-loss coverage, several cash routes now sit far below the list price.

NovoCare, Novo Nordisk’s own self-pay pharmacy, is the most direct:

• Wegovy injection: $349 a month for the standard doses (0.25 through 2.4 mg), and $399 a month for the higher-dose Wegovy HD 7.2 mg. New patients can pay $199 a month for the first two monthly fills of the 0.25 and 0.5 mg starting doses — an introductory offer running through June 30, 2026.
• Oral Wegovy: from $149 a month for the lower tablet doses, rising to around $299 a month for higher doses.
• TrumpRx: the federal pricing portal launched in early 2026 also offers Wegovy at roughly $350 a month, with no insurance or income requirement.

Two notes on the cash routes. Pharmacy discount cards such as GoodRx exist, but for Wegovy they reduce the price only modestly and stay well above NovoCare’s self-pay figures — they mainly help if you need an immediate local pickup. And Novo Nordisk’s Patient Assistance Program, which provides some of its medicines free to low-income patients, does not currently include Wegovy, so there is no straightforward route to free Wegovy.

The lowest-cost route of all is usually compounded semaglutide — the same active drug, semaglutide, prepared by compounding pharmacies, typically priced around $150 to $300 a month. It is not an FDA-approved finished product, and it carries real trade-offs around dosing, formulation and quality control that we cover in our guide to compounded semaglutide. For the wider picture across every GLP-1 and every payment route, see our full GLP-1 cost guide; for how Wegovy’s pricing compares with Ozempic’s, our Ozempic cost guide.

Frequently Asked Questions

How much does Wegovy cost without insurance in 2026?

The list price is about $1,350 a month, but few people pay it. Through Novo Nordisk’s NovoCare self-pay pharmacy, the Wegovy injection is $349 a month — or $199 a month for the first two fills for new patients, through June 30, 2026. Oral Wegovy starts around $149 a month. The federal TrumpRx portal lists Wegovy at roughly $350 a month.

Does Medicare cover Wegovy?

Standard Medicare Part D does not cover Wegovy for weight loss alone, but it can cover it for the cardiovascular indication in beneficiaries with heart disease and obesity or overweight. Separately, the new Medicare GLP-1 Bridge — running July 1, 2026 through December 31, 2027 — gives eligible Part D members Wegovy for a $50 monthly copay for weight management.

Why doesn’t my insurance cover Wegovy?

Many commercial plans exclude weight-loss medication as a category, regardless of the specific drug. Even when a plan does cover Wegovy, it often requires prior authorization and a BMI threshold. It is worth checking whether your plan covers Wegovy for the cardiovascular indication, which is sometimes handled separately from weight-loss coverage.

Is the Wegovy pill cheaper than the injection?

Through NovoCare self-pay, yes — the oral Wegovy tablet starts around $149 a month, below the $349 self-pay price of the injection. The list price is the same, roughly $1,350, for both forms. Oral Wegovy is approved for chronic weight management, the same use as the injection.

Can I get Wegovy for free?

There is no straightforward route to free Wegovy. Novo Nordisk’s Patient Assistance Program, which provides some medicines at no cost to low-income patients, does not currently include Wegovy. The lowest-cost options are the $25-a-month savings card for patients with commercial coverage, or the $50 monthly copay through the Medicare GLP-1 Bridge for eligible beneficiaries.

The Bottom Line

Wegovy’s $1,350 list price is no longer the number that decides things. In 2026, what you pay depends on which door you walk through. With commercial insurance that covers weight-loss medication, the savings card can mean about $25 a month; without that coverage, you are looking at cash pricing. For Medicare beneficiaries, the new GLP-1 Bridge brings a $50 monthly copay from July 2026 through 2027 — a genuine change after years of no coverage at all. Paying cash, NovoCare self-pay runs $349 a month for the injection and from $149 for the oral form, with compounded semaglutide usually the least expensive route of all.

The single most useful step is to find out, specifically, what your plan covers and which programs you qualify for — because for Wegovy in 2026, the gap between the list price and the real price has never been wider.

This article is general information, not medical or financial advice. Prices, programs and Medicare details reflect the situation as of May 2026 and change frequently; confirm current pricing and eligibility with NovoCare, your insurer, CMS or your pharmacy before making decisions.